{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T07:20:54Z","timestamp":1788247254449,"version":"build-2803163510"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pulmonary Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.pupt.2021.102058","type":"journal-article","created":{"date-parts":[[2021,7,20]],"date-time":"2021-07-20T01:57:15Z","timestamp":1626746235000},"page":"102058","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["Clofazimine for treatment of multidrug-resistant non-tuberculous mycobacteria"],"prefix":"10.1016","volume":"70","author":[{"given":"Herman O.I.","family":"Pfaeffle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reem M.","family":"Alameer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary H.","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric R.","family":"Houpt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9055-3247","authenticated-orcid":false,"given":"Dana P.","family":"Albon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott K.","family":"Heysell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pupt.2021.102058_bib1","first-page":"107","article-title":"Nontuberculous mycobacteria and associated diseases","volume":"119","author":"Wolinsky","year":"1979","journal-title":"Am. Rev. Respir. Dis."},{"key":"10.1016\/j.pupt.2021.102058_bib2","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ccm.2014.10.002","article-title":"Epidemiology of human pulmonary infection with non-tuberculous mycobacteria: a review","volume":"36","author":"Prevots","year":"2015","journal-title":"Clin. Chest Med."},{"key":"10.1016\/j.pupt.2021.102058_bib3","first-page":"123","article-title":"Update on pulmonary disease due to non-tuberculous mycobacteria","volume":"45","author":"Stout","year":"2016","journal-title":"Int. J. Infect. Dis. IJID Off. Publ. Int. Soc. Infect. Dis."},{"key":"10.1016\/j.pupt.2021.102058_bib4","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1080\/00039896.1971.10665813","article-title":"The ecology of the atypicalmycobacteria","volume":"22","author":"Chapman","year":"1971","journal-title":"Arch. Environ. Health"},{"key":"10.1016\/j.pupt.2021.102058_bib5","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1164\/rccm.200604-571ST","article-title":"An official ATS\/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases","volume":"175","author":"Griffith","year":"2007","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.pupt.2021.102058_bib6","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.chest.2017.04.175","article-title":"Safety and effectiveness of clofazimine for primary and refractory nontuberculous mycobacterial infection","volume":"152","author":"Martiniano","year":"2017","journal-title":"Chest"},{"key":"10.1016\/j.pupt.2021.102058_bib7","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.3201\/2109.141634","article-title":"Mycobacterium abscessus complex infections in humans","volume":"21","author":"Lee","year":"2015","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.pupt.2021.102058_bib8","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(13)60632-7","article-title":"Whole-genome sequencing to identify transmission of Mycobacterium abscessus between patients with cystic fibrosis: a retrospective cohort study","volume":"381","author":"Bryant","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.pupt.2021.102058_bib9","doi-asserted-by":"crossref","first-page":"90","DOI":"10.3390\/microorganisms7030090","article-title":"Mycobacterium abscessus: environmental bacterium turned clinical nightmare","volume":"7","author":"Lopeman","year":"2019","journal-title":"Microorganisms"},{"issue":"Suppl 1","key":"10.1016\/j.pupt.2021.102058_bib10","doi-asserted-by":"crossref","first-page":"i1","DOI":"10.1136\/thoraxjnl-2015-207360","article-title":"US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis","volume":"71","author":"Floto","year":"2016","journal-title":"Thorax"},{"key":"10.1016\/j.pupt.2021.102058_bib11","article-title":"Bedaquiline as a potential agent in the treatment of Mycobacterium abscessus infections","volume":"49","author":"Vesenbeckh","year":"2017","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.pupt.2021.102058_bib12","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00155-17","article-title":"Rifabutin is active against Mycobacterium abscessus complex","volume":"61","author":"Aziz","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.pupt.2021.102058_bib13","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1177\/106002809102500513","article-title":"A review of its use in leprosy and Mycobacterium avium complex infection","volume":"25","author":"Garrelts","year":"1991","journal-title":"DICP"},{"key":"10.1016\/j.pupt.2021.102058_bib14","doi-asserted-by":"crossref","first-page":"17","DOI":"10.47276\/lr.82.1.17","article-title":"Adverse effects of multi-drug therapy in leprosy, a two years' experience (2006-2008) in tertiary health care centre in the tribal region of Chhattisgarh State (Bastar, Jagdalpur)","volume":"82","author":"Singh","year":"2011","journal-title":"Lepr. Rev."},{"key":"10.1016\/j.pupt.2021.102058_bib15","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1093\/cid\/civ027","article-title":"Clofazimine for the treatment of multidrug-resistant tuberculosis: prospective, multicenter, randomized controlled study in China","volume":"60","author":"Tang","year":"2015","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"10.1016\/j.pupt.2021.102058_bib16","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.cmi.2018.11.010","article-title":"Clofazimine for the treatment of multidrug-resistant tuberculosis","volume":"25","author":"Lange","year":"2019","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.pupt.2021.102058_bib17","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2013-004143","article-title":"Safety and availability of clofazimine in the treatment of multidrug and extensively drug-resistant tuberculosis: analysis of published guidance and meta-analysis of cohort studies","volume":"4","author":"Hwang","year":"2014","journal-title":"BMJ Open"},{"key":"10.1016\/j.pupt.2021.102058_bib18","author":"Who"},{"key":"10.1016\/j.pupt.2021.102058_bib19","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00072-18","article-title":"In vitro activity of clofazimine against nontuberculous mycobacteria isolated in beijing, China","volume":"62","author":"Luo","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.pupt.2021.102058_bib20","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/MCP.0000000000000570","article-title":"New drugs to treat difficult tuberculous and nontuberculous mycobacterial pulmonary disease","volume":"25","author":"Lee","year":"2019","journal-title":"Curr. Opin. Pulm. Med."},{"key":"10.1016\/j.pupt.2021.102058_bib21","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.ijantimicag.2009.12.008","article-title":"High efficacy of clofazimine and its synergistic effect with amikacin against rapidly growing mycobacteria","volume":"35","author":"Shen","year":"2010","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.pupt.2021.102058_bib22","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/00002030-199703110-00008","article-title":"Clarithromycin and ethambutol with or without clofazimine for the treatment of bacteremic Mycobacterium avium complex disease in patients with HIV infection","volume":"11","author":"Chaisson","year":"1997","journal-title":"AIDS Lond. Engl."},{"key":"10.1016\/j.pupt.2021.102058_bib23","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1378\/chest.124.4.1482","article-title":"Treatment of Mycobacterium avium-intracellulare complex lung disease with a macrolide, ethambutol, and clofazimine","volume":"124","author":"Field","year":"2003","journal-title":"Chest"},{"key":"10.1016\/j.pupt.2021.102058_bib24","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.jiac.2014.05.010","article-title":"Treatment outcomes of refractory MAC pulmonary disease treated with drugs with unclear efficacy","volume":"20","author":"Jo","year":"2014","journal-title":"J. Infect. Chemother. Off. J. Jpn. Soc. Chemother."},{"key":"10.1016\/j.pupt.2021.102058_bib25","unstructured":"Long-term Follow-up of Mycobacterium avium Complex Lung Disease in Patients Treated With Regimens Including Clofazimine and\/or Rifampin. - PubMed - NCBI. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26513209."},{"key":"10.1016\/j.pupt.2021.102058_bib26","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02052-16","article-title":"Clofazimine-containing regimen for the treatment of Mycobacterium abscessus lung disease","volume":"61","author":"Yang","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.pupt.2021.102058_bib27","doi-asserted-by":"crossref","unstructured":"Carey, G. B. et al. Clinical outcomes of clofazimine use for rapidly growing mycobacterial infections. Open Forum Infect. Dis. doi:10.1093\/ofid\/ofz456.","DOI":"10.1093\/ofid\/ofz456"},{"key":"10.1016\/j.pupt.2021.102058_bib28","series-title":"New Methodology for Nontuberculous Mycobacteria-Drug Resistance","author":"Khare","year":"2018"},{"key":"10.1016\/j.pupt.2021.102058_bib29","series-title":"Department of Microbiology at UT Health Science Center","author":"Joanne","year":"2019"},{"key":"10.1016\/j.pupt.2021.102058_bib30","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00170-2018","article-title":"Treatment outcome definitions in nontuberculous mycobacterial pulmonary disease: an NTM-NET consensus statement","volume":"51","author":"van Ingen","year":"2018","journal-title":"Eur. Respir. J."}],"container-title":["Pulmonary Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553921000705?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553921000705?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T21:30:23Z","timestamp":1761082223000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1094553921000705"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":30,"alternative-id":["S1094553921000705"],"URL":"https:\/\/doi.org\/10.1016\/j.pupt.2021.102058","relation":{},"ISSN":["1094-5539"],"issn-type":[{"value":"1094-5539","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clofazimine for treatment of multidrug-resistant non-tuberculous mycobacteria","name":"articletitle","label":"Article Title"},{"value":"Pulmonary Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pupt.2021.102058","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102058"}}